Document is current
Any future updates will be listed below
-
Authors
Lloyd, Kate
Newman, Lisa A.
Glass, Charity
Ogayo, Esther R.
Mayer, Erica L.
Chavez-MacGregor, Mariana
Freedman, Rachel A.
King, Tari A.
Mittendorf, Elizabeth A.
Kantor, Olga https://orcid.org/0000-0001-8699-7208
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 27 July 2025
First Online: 4 August 2025
Declarations
:
: TAK reports speaker honoraria for Exact Sciences, compensated service on the FES Steering Committee for GE Healthcare, compensated service for advisory board role for Veracyte, and compensated service as faculty for PrecisCa cancer information service. EAM reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. EAM also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors.
: Data for this analysis were obtained with permission through the National Clinical Trials Network data archive of the National Cancer Institute. Secondary data use was approved by the Brigham and Women’s Hospital Institutional Review Board. Informed consent for trial participation was obtained from all participants in the original ECOG-ACRIN EA1131 clinical trial population. Additional consent was waived for the secondary analysis due to the de-identified nature of the dataset for this project.
